A prospective, single-center, and open-label clinical pilot study reveals that patients with mild-to-severe AD who received etanercept, a TNFα inhibitor, given by perispinal extrathecal administration for 6 months had improved cognitive performance [83]. Here, TNF is linked to Alzheimer disease.